🇪🇺EU · EMAApplication withdrawn

Docetaxel Mylan(docetaxel)

Carcinoma, Non-Small-Cell Lung;Breast Neoplasms;Head and Neck Neoplasms;Stomach Neoplasms;Adenocarcinoma;Prostatic Neoplasms

Marketing Authorisation Holder: Mylan S.A.S.

INN: docetaxel

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Docetaxel Mylan — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Ask about Docetaxel Mylan Create Free Account

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.